Transcriptome Profiling of Human Dermal Fibroblasts Treated with 4 Phosphodiesterase Inhibitors Across Multiple Dose Gradients
This study presents RNA-sequencing data from Human Primary Dermal Fibroblast, Neonatal (HDFn) cells treated with four phosphodiesterase (PDE) inhibitors—roflumilast, rolipram, cilostazol, and milrinone—across a 2-fold serial dilution range spanning from 7.8 nM to 8,000 nM. The dataset includes biological replicates for each treatment condition and dose. Total RNA was extracted and sequenced on the DNBSEQ-G400 platform. The processed data includes gene-level read counts and differential gene expression results. This dataset enables dose-dependent transcriptional profiling of PDE inhibitors, providing a resource for drug response and perturbation signature analysis. Overall design: HDFn cells were cultured in low-serum fibroblast medium and treated with four PDE inhibitors at eleven concentrations ranging from 7.8 nM to 8,000 nM for 24 hours. Total RNA was extracted, and RNA-seq libraries were prepared using BGI's DNBSEQ-G400 platform. Sequencing reads were processed through quality control, trimming, alignment to the human reference genome (GRCh38 v34), and quantification using HTSeq-count. Differential gene expression analysis and perturbation impact scoring were performed to characterize transcriptional changes across the dose gradient. Each treatment condition includes biological replicates to ensure reproducibility.